Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial
- Submitting institution
-
The University of Liverpool
- Unit of assessment
- 2 - Public Health, Health Services and Primary Care
- Output identifier
- 15927
- Type
- D - Journal article
- DOI
-
10.1016/S1470-2045(17)30084-0
- Title of journal
- The Lancet Oncology
- Article number
- -
- First page
- 486
- Volume
- 18
- Issue
- 4
- ISSN
- 1470-2045
- Open access status
- Deposit exception
- Month of publication
- March
- Year of publication
- 2017
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
23
- Research group(s)
-
C - Trials & Methodology
- Citation count
- 28
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- TC contributed to the development of the study design and was responsible for detailed statistical analysis. TC also contributed to the interpretation of the results, and preparation of the initial draft, and approved the final version.
- Non-English
- No
- English abstract
- -
